Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q1 FY2020 Earnings Presentation
12 slides from Eris Lifesciences's earnings presentation, July 2019
Slide 1: Eris Lifesciences Ltd Q1 FY20 Investor Presentation
ERIS LIFESCIENCES LTD Q1 FY 20 INVESTOR PRESENTATION 1
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 3: Q1 FY20 – Business Highlights
Q1 FY 20 – BUSINESS HIGHLIGHTS • Strong Growth Momentum Retained • Eris launches Saarthi 2.0 with PlexusMD in July 19 • Substantial yoy growth in Q1 20 (12.8% vs 7.9% for IPM) • Unique online learning platform for Doctors with medical adds to the growth momentum in H2 19 (16.7% vs 9.9% for content,
Slide 4: Q1 FY20 – Financial Highlights
Q1 FY 20 – FINANCIAL HIGHLIGHTS Q1 20 Financial Performance 10.0% 18.0% 17.5% yoy growth in Sales yoy growth in EBITDA yoy growth in Net Profit • Full Prepayment of external borrowings from internal accruals gives company a Debt Free status • Strong expansion in EBITDA margin led by increase in YPM
Slide 5: Q1 FY20 – Income Statement
Q1 FY 20 – INCOME STATEMENT Consolidated Q1 20 Q1 20 Q1 19 INR mn yoy GR Sale of Products 2,719 2,471 10.0% Other Operating Income 24 37 -34.6% Revenue from Operations 2,743 2,508 9.4% Gross Profit 2,284 2,119 7.8% Gross Profit Margins 83.3% 84.5% Employee cost 471 491 -3.9% as % of Revenue 17.2% 19
Slide 6: Q1 FY20 – Entity Wise Sales
Q1 FY 20 – ENTITY WISE SALES Consolidated Q1 20 Sale of Products Q1 20 Q1 19 Q1 20 Q1 20 Q1 19 INR mn yoy GR INR mn yoy GR Sale of Products 2,719 2,471 10.0% Consolidated 2,719 2,471 10.0% Other Operating Income 24 37 -34.6% Revenue from Operations 2,743 2,508 9.4% Stand alone 2,598 2,227 16.6% Gros
Slide 7: Substantial Secondary Growth
Q1 FY 20 – SUBSTANTIAL SECONDARY GROWTH Q1 20 yoy GR Total 12.8% 7.9% Eris IPM Chronic +Chronic Sub Chronic + SubTherapies Acute Therapies Chronic 14.0% 8.9% 6.3% 6.7% Eris IPM Eris IPM THERAPY WISE SALES GROWTH TRENDS Source: AIOCD Jun’19 7
Slide 8: Prescription Ranking
Q1 FY 20 – PRESCRIPTION RANKING Prescription Ranking* 4 2 4 CARDIOLOGY DIABETOLOGY GASTRO 3 6 CONSULTING NEUROLOGY PHYSICIAN Source: SMSRC Jun’19 * Rx Rank in Represented Market (Rx May-Jun’19) 8
Slide 9: 10 Year Financial Highlight
10 YEAR FINANCIAL HIGHLIGHT 9,822 8,556 7,495 5,970 5,456 5,088 3,931 3,449 2,739 2,719 2,054 2,911 1,045 955 • 356 • 841 FY 09 FY 10 FY 11 FY 12 FY 13 FY 14 FY 15 FY 16 FY 17 FY 18 FY 19 Q1 20 Op Revenue Op EBITDA PAT INR million FY 2009 FY 2010 FY 2011 FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 FY 20
Slide 10: Manufacturing Facility - Guwahati
MANUFACTURING FACILITY - GUWAHATI KEY METRICS FY 17 FY 18 FY 19 Manufacturing at Guwahati Plant 78% 66% 61% As % of Op Revenue Effective Tax Rate as % of PBT 9% 6% 8% 10
Slide 11: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors As on As on As on Sr No Name of Shareholder 0.2% 17 July 19 31 Dec 18 30 June 18 11.8% DIIs Other 445 * 687 * 685 * Promoters 56.23% 56.04% 55.93% 7.8% 1 Motilal Oswal Mutual Fund 3.97% 3.86% 3.59% FPIs 2 Aditya Birla S
Slide 12: Thank You
THANK YOU Lifesciences